Molybdophosphoric acid hydrate, min. 99%, pa, ACS, 25 g, glass packaging

LETERMOVIR, 95%, 250mg

2-(2-(Difluoromethyl)-4,5-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 500mg

4-Chloro-1,3-dimethyl-1H-pyrazole-5-carboxylic acid, 95.0%, 5g

2-CHLORO-6-METHOXYQUINOLINE-3-CARBALDEHYDE, 97.0%, 1g

3,5-Dimethylcyclohex-2-en-1-one, 95%, 250mg

5-Chloro-2-(chloromethyl)benzo[d]oxazole, 95.0%, 250mg

3-IODO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBOXYLIC ACID METHYL ESTER, 95.0%, 10g

tert-butyl 4-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate, 95.0%, 5g

Ethyl 4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylate, 97%, 250mg

N-Hydroxy-N-phenylbenzamide, 95.0%, 1g

2-[2-(4-ethoxyphenyl)-1H-1,3-benzodiazol-6-yl]-6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazole trihydrochloride, 98%, 250mg

2-(Benzo[b]thiophen-2-yl)ethan-1-amine hydrochloride, 95%, 5g